brontictuzumab   Click here for help

GtoPdb Ligand ID: 11361

Synonyms: OMP-52M51 | OMP52M51
Compound class: Antibody
Comment: Brontictuzumab (OMP-52M51) is a fully human anti-NOTCH1 monoclonal antibody [4-5]. It was developed by OncoMed Pharmaceuticals. Peptide sequence analysis reveals that the heavy and light chains that make up brontictuzumab are claimed in Oncomed patent US20140011271A1 [3]. The heavy chain is SEQ ID NO:22 (52M51-H4), and the light chain is SEQ ID NO:26 (2M51L3), making the brontictuzumab structure 52M51H4L3.
Click here for help
No information available.
Summary of Clinical Use Click here for help
Brontictuzumab (OMP-52M51) was advanced to early phase clinical studies to determine its potential to treat advanced lymphoid and solid malignancies [2]. As of January 2021 there were no active trials on
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01778439 A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors Phase 1 Interventional Mereo BioPharma Target engagement was confirmed in this study, and an efficacy signal was detected in participants with adenoid cystic carcinoma and NOTCH1 pathway activation. 1